Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/european-medicines-agency-ema-grants-orphan-drug-designation-for-moleculins-treatment-of-acute-myeloid-leukemia-aml-302120221.html
https://www.prnewswire.com/news-releases/moleculin-announces-presentation-of-positive-data-demonstrating-high-anti-cancer-activity-of-annamycin-and-non-cardiotoxic-properties-302112418.html
https://www.prnewswire.com/news-releases/moleculin-to-present-at-the-medinvest-biotech--pharma-investor-conference-302102695.html
https://www.prnewswire.com/news-releases/moleculin-to-participate-in-the-virtual-investor-lunch-break-the-moleculin-opportunity-302100348.html
https://www.prnewswire.com/news-releases/moleculin-announces-us-patent-issue-notification-for-annamycin-targeting-unmet-need-in-aml-302100349.html
https://www.prnewswire.com/news-releases/moleculin-to-present-at-the-36th-annual-roth-conference-302086104.html
https://www.prnewswire.com/news-releases/moleculin-announces-2023-year-end-annamycin-clinical-trials-preliminary-data-and-2024-expectations-for-multiple-data-readouts-and-transition-to-pivotal-phase-2b3-302042622.html
https://www.prnewswire.com/news-releases/moleculin-announces-positive-interim-data-in-annamycin-clinical-trials-mb-106-aml-trial-complete-response-cr-rate-of-38-and-mb-107-sts-lung-mets-trial-median-phase-1b-extended-overall-survival-of-11-months-301985417.html
https://www.prnewswire.com/news-releases/moleculin-doses-first-subjects-in-phase-2-portion-of-clinical-trial-evaluating-annamycin-in-combination-with-cytarabine-ara-c-for-the-treatment-of-acute-myeloid-leukemia-aml-301943789.html
https://www.prnewswire.com/news-releases/moleculin-announces-new-positive-independent-report-of-no-cardiotoxicity-in-annamycin-301930336.html